Brokerages forecast that Veru Inc (NASDAQ:VERU) will post $9.26 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Veru’s earnings, with the lowest sales estimate coming in at $8.20 million and the highest estimate coming in at $11.19 million. Veru posted sales of $5.20 million in the same quarter last year, which suggests a positive year-over-year growth rate of 78.1%. The firm is scheduled to announce its next quarterly earnings results on Thursday, December 12th.
According to Zacks, analysts expect that Veru will report full year sales of $32.35 million for the current financial year, with estimates ranging from $31.30 million to $34.26 million. For the next fiscal year, analysts anticipate that the company will report sales of $34.96 million, with estimates ranging from $33.90 million to $35.97 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Veru.
Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). The business had revenue of $9.73 million for the quarter, compared to analyst estimates of $8.11 million. Veru had a negative net margin of 59.68% and a negative return on equity of 50.14%.
VERU has been the topic of several analyst reports. ValuEngine upgraded shares of Veru from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating on shares of Veru in a research report on Thursday, October 3rd. Brookline Capital Management initiated coverage on shares of Veru in a research report on Monday, July 29th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Veru from a “hold” rating to a “sell” rating in a research report on Saturday, October 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $5.71.
Shares of NASDAQ VERU traded up $0.03 during trading hours on Tuesday, hitting $2.01. 118,800 shares of the stock were exchanged, compared to its average volume of 155,400. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.20 and a current ratio of 1.47. The company has a market cap of $131.38 million, a PE ratio of -5.15 and a beta of 0.33. The company’s fifty day simple moving average is $2.05 and its two-hundred day simple moving average is $1.97. Veru has a 1-year low of $1.18 and a 1-year high of $2.49.
In other Veru news, CFO Michele Greco purchased 20,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $1.84 per share, with a total value of $36,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mitchell Shuster Steiner sold 14,164 shares of the firm’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $2.11, for a total transaction of $29,886.04. In the last 90 days, insiders acquired 47,000 shares of company stock worth $89,040 and sold 60,000 shares worth $121,358. Company insiders own 29.50% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its stake in shares of Veru by 1.4% during the second quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock valued at $3,078,000 after acquiring an additional 20,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Veru by 183.1% during the second quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after acquiring an additional 169,550 shares during the last quarter. BlackRock Inc. raised its stake in shares of Veru by 65.4% during the second quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after acquiring an additional 90,530 shares during the last quarter. Wedge Capital Management L L P NC bought a new position in shares of Veru during the second quarter valued at $394,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of Veru during the third quarter valued at $25,000. 8.85% of the stock is owned by hedge funds and other institutional investors.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.